Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 12/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26620578 | 0.89 | MTNR1A (0.42) | MTNR1AMTNR1BMCL1ALDH1A1KDM4E | |
| SCHEMBL27593266 | 0.84 | MTNR1A (0.45) | MTNR1AMTNR1BMCL1KMOALDH1A1 | |
| SCHEMBL8163392 | 0.81 | MAPK1 (0.60) | MTNR1AMTNR1BALDH1A1MAPK1 | |
| SCHEMBL8303038 | 0.80 | MCL1 (0.57) | MTNR1AMTNR1BMCL1BCL2 | |
| SCHEMBL27732822 | 0.80 | HTR7 (0.54) | MTNR1AMTNR1BMCL1 | |
| SCHEMBL6919592 | 0.79 | HTR7 (0.57) | MCL1BCL2 | |
| SCHEMBL4653660 | 0.77 | KDM4E (0.44) | MTNR1AMTNR1BMCL1KMOALDH1A1 | |
| SCHEMBL5778935 | 0.76 | MAPK1 (0.39) | MTNR1AMTNR1BMCL1KMOALDH1A1 | |
| SCHEMBL27593312 | 0.76 | PRKCI (0.47) | MTNR1AMTNR1BMCL1ALDH1A1MAPK1 | |
| SCHEMBL27639166 | 0.75 | MTNR1A (0.46) | MTNR1AMTNR1BMCL1KDM4EBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100509802-C | Heteroaryl deravatives as PPAR activators | HOFFMANN LA ROCHE (CH) | 2009-07-08 | — | — | CN | disclosed |
| CN-100467463-C | Pyrazolylindolyl derivatives as PPAR activators | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | CN | disclosed |
| CN-101001837-A | Indole derivatives comprising an acetylene group as PPAR activators | HOFFMANN LA ROCHE (CH) | 2007-07-18 | — | — | CN | disclosed |
| CN-1930150-A | Pyrazolyl indolyl derivatives as PPAR activators | HOFFMANN LA ROCHE (CH) | 2007-03-14 | — | — | CN | disclosed |
| CN-1878768-A | heteroaryl derivatives as PPAR activators | HOFFMANN LA ROCHE (CH) | 2006-12-13 | — | — | CN | disclosed |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | MTNR1A 3189/4885MTNR1B 2041/4885MCL1 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.